Literature DB >> 31905251

Genomic and clinical characterization of stromal infiltration markers in prostate cancer.

Brandon A Mahal1, Mohammed Alshalalfa1,2, Shuang G Zhao3, Himisha Beltran1, William S Chen2, Fallon Chipidza1, Elai Davicioni4, R Jeffrey Karnes5, Sheng-Yu Ku1, Tamara L Lotan6, Vinayak Muralidhar1, Timothy R Rebbeck1,7, Edward M Schaeffer8, Daniel E Spratt3, Felix Y Feng2, Paul L Nguyen1.   

Abstract

BACKGROUND: The progression of prostate cancer is a complex, multistep process that involves molecular alterations in cells of the tumor and the microenvironment, with associated interactions between the stroma and epithelium. Genomic expression analyses of stromal infiltration markers were performed to determine the significance thereof in prostate cancer.
METHODS: Genome-wide expression profiles of formalin-fixed, paraffin-embedded radical prostatectomy samples were evaluated from a prospective registry cohort (n = 5239) and 3 retrospective institutional cohorts (n = 1135). Two independent stromal gene expression signatures implied stromal infiltration. Cox proportional hazards regression defined the association between stromal infiltration expression and metastasis-free survival (MFS).
RESULTS: Stromal expression scores were correlated with stromal signature genes and with other key stromal markers (CAV1, VIM, and TAGLN), basal activity, and CD3 and CD4 immune biomarkers (r > 0.5 for all). The top decile of stromal expression was associated with high genomic risk scores (Decipher ≥ 0.6) , high Cancer of the Prostate Risk Assessment-Postsurgical scores, Gleason 9 to 10 disease, and a higher risk for metastasis (hazard ratio, 2.35; 95% CI, 1.37-4.02; P = .001). A higher stromal infiltration score was also associated with decreased expression of DNA repair genes and higher radiation sensitivity genomic scores. Postoperative radiation therapy (RT) was associated with an MFS benefit for patients with high stromal scores, but not for patients with low stromal scores (Pinteraction  = .02).
CONCLUSIONS: Expression of stromal infiltration markers is correlated with prostate cancer aggressiveness/progression and may be predictive of a response to RT. Stromal infiltration markers should be studied and considered for incorporation into clinical prognostication and decision making.
© 2020 American Cancer Society.

Entities:  

Keywords:  Decipher; genomics; prostatic neoplasms; stromal infiltration; tumor microenvironment

Mesh:

Substances:

Year:  2020        PMID: 31905251      PMCID: PMC7332205          DOI: 10.1002/cncr.32688

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

2.  Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications.

Authors:  Mohammed Alshalalfa; Paul L Nguyen; Himisha Beltran; William S Chen; Elai Davicioni; Shuang G Zhao; Timothy R Rebbeck; Edward M Schaeffer; Tamara L Lotan; Felix Y Feng; Brandon A Mahal
Journal:  Eur Urol Oncol       Date:  2019-06-02

3.  Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores.

Authors:  Brandon A Mahal; Mohammed Alshalalfa; Daniel E Spratt; Elai Davicioni; Shuang G Zhao; Felix Y Feng; Timothy R Rebbeck; Paul L Nguyen; Franklin W Huang
Journal:  Eur Urol       Date:  2019-01-22       Impact factor: 20.096

4.  Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis.

Authors:  Shuang G Zhao; S Laura Chang; Daniel E Spratt; Nicholas Erho; Menggang Yu; Hussam Al-Deen Ashab; Mohammed Alshalalfa; Corey Speers; Scott A Tomlins; Elai Davicioni; Adam P Dicker; Peter R Carroll; Matthew R Cooperberg; Stephen J Freedland; R Jeffrey Karnes; Ashley E Ross; Edward M Schaeffer; Robert B Den; Paul L Nguyen; Felix Y Feng
Journal:  Lancet Oncol       Date:  2016-10-12       Impact factor: 41.316

Review 5.  The biology and function of fibroblasts in cancer.

Authors:  Raghu Kalluri
Journal:  Nat Rev Cancer       Date:  2016-08-23       Impact factor: 60.716

Review 6.  Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease.

Authors:  Daniel E Spratt; Kasra Yousefi; Samineh Deheshi; Ashley E Ross; Robert B Den; Edward M Schaeffer; Bruce J Trock; Jingbin Zhang; Andrew G Glass; Adam P Dicker; Firas Abdollah; Shuang G Zhao; Lucia L C Lam; Marguerite du Plessis; Voleak Choeurng; Zaid Haddad; Christine Buerki; Elai Davicioni; Sheila Weinmann; Stephen J Freedland; Eric A Klein; R Jeffrey Karnes; Felix Y Feng
Journal:  J Clin Oncol       Date:  2017-03-30       Impact factor: 44.544

7.  Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.

Authors:  R Jeffrey Karnes; Eric J Bergstralh; Elai Davicioni; Mercedeh Ghadessi; Christine Buerki; Anirban P Mitra; Anamaria Crisan; Nicholas Erho; Ismael A Vergara; Lucia L Lam; Rachel Carlson; Darby J S Thompson; Zaid Haddad; Benedikt Zimmermann; Thomas Sierocinski; Timothy J Triche; Thomas Kollmeyer; Karla V Ballman; Peter C Black; George G Klee; Robert B Jenkins
Journal:  J Urol       Date:  2013-06-11       Impact factor: 7.450

8.  Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy.

Authors:  Nicholas Erho; Anamaria Crisan; Ismael A Vergara; Anirban P Mitra; Mercedeh Ghadessi; Christine Buerki; Eric J Bergstralh; Thomas Kollmeyer; Stephanie Fink; Zaid Haddad; Benedikt Zimmermann; Thomas Sierocinski; Karla V Ballman; Timothy J Triche; Peter C Black; R Jeffrey Karnes; George Klee; Elai Davicioni; Robert B Jenkins
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

9.  A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy.

Authors:  Tohru Nakagawa; Thomas M Kollmeyer; Bruce W Morlan; S Keith Anderson; Eric J Bergstralh; Brian J Davis; Yan W Asmann; George G Klee; Karla V Ballman; Robert B Jenkins
Journal:  PLoS One       Date:  2008-05-28       Impact factor: 3.240

10.  Systematic pan-cancer analysis of tumour purity.

Authors:  Dvir Aran; Marina Sirota; Atul J Butte
Journal:  Nat Commun       Date:  2015-12-04       Impact factor: 14.919

View more
  2 in total

1.  Robust prognostic model based on immune infiltration-related genes and clinical information in ovarian cancer.

Authors:  Xi Zhang; Weikaixin Kong; Miaomiao Gao; Weiran Huang; Chao Peng; Zhuo Huang; Zhengwei Xie; Hongyan Guo
Journal:  J Cell Mol Med       Date:  2022-06-23       Impact factor: 5.295

Review 2.  Tumor Microenvironment in Prostate Cancer: Toward Identification of Novel Molecular Biomarkers for Diagnosis, Prognosis, and Therapy Development.

Authors:  Hisham F Bahmad; Mohammad Jalloul; Joseph Azar; Maya M Moubarak; Tamara Abdul Samad; Deborah Mukherji; Mohamed Al-Sayegh; Wassim Abou-Kheir
Journal:  Front Genet       Date:  2021-03-26       Impact factor: 4.599

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.